TY - JOUR
T1 - Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies
AU - European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY)
AU - Sangro, Bruno
AU - Maini, Carlo Ludovico
AU - Ettorre, Giuseppe Maria
AU - Cianni, Roberto
AU - Golfieri, Rita
AU - Gasparini, Daniele
AU - Ezziddin, Samer
AU - Paprottka, Philipp M
AU - Fiore, Francesco
AU - Van Buskirk, Mark
AU - Bilbao, Jose Ignacio
AU - Salvatori, Rita
AU - Giampalma, Emanuela
AU - Geatti, Onelio
AU - Wilhelm, Kai
AU - Hoffmann, Ralf Thorsten
AU - Izzo, Francesco
AU - Iñarrairaegui, Mercedes
AU - Urigo, Carlo
AU - Cappelli, Alberta
AU - Vit, Alessandro
AU - Ahmadzadehfar, Hojjat
AU - Jakobs, Tobias Franz
AU - Sciuto, Rosa
AU - Pizzi, Giuseppe
AU - Lastoria, Secondo
PY - 2018/9
Y1 - 2018/9
N2 - PURPOSE: Radioembolisation is part of the multimodal treatment of hepatocellular carcinoma (HCC) at specialist liver centres. This study analysed the impact of prior treatment on tolerability and survival following radioembolisation.METHODS: This was a retrospective analysis of 325 consecutive patients with a confirmed diagnosis of HCC, who received radioembolisation with yttrium-90 resin microspheres at eight European centres between September 2003 and December 2009. The decision to treat was based on the clinical judgement of multidisciplinary teams. Patients were followed from the date of radioembolisation to last contact or death and the nature and severity of all adverse events (AEs) recorded from medical records.RESULTS: Most radioembolisation candidates were Child-Pugh class A (82.5%) with multinodular HCC (75.9%) invading both lobes (53.1%); 56.3% were advanced stage. Radioembolisation was used first-line in 57.5% of patients and second-line in 34.2%. Common prior procedures were transarterial (chemo)embolisation therapies (27.1%), surgical resection/transplantation (17.2%) and ablation (8.6%). There was no difference in AE incidence and severity between prior treatment subgroups. Median (95% confidence interval [CI]) survival following radioembolisation was similar between procedure-naive and prior treatment groups for Barcelona Clinic Liver Cancer (BCLC) stage A: 22.1 months (15.1-45.9) versus 30.9 months (19.6-46.8); p = 0.243); stage B: 18.4 months (11.2-19.4) versus 22.8 months (10.9-34.2); p = 0.815; and stage C: 8.8 months (7.1-10.8) versus 10.8 months (7.7-12.6); p = 0.976.CONCLUSIONS: Radioembolisation is a valuable treatment option for patients who relapse following surgical, ablative or vascular procedures and remain suitable candidates for this treatment.
AB - PURPOSE: Radioembolisation is part of the multimodal treatment of hepatocellular carcinoma (HCC) at specialist liver centres. This study analysed the impact of prior treatment on tolerability and survival following radioembolisation.METHODS: This was a retrospective analysis of 325 consecutive patients with a confirmed diagnosis of HCC, who received radioembolisation with yttrium-90 resin microspheres at eight European centres between September 2003 and December 2009. The decision to treat was based on the clinical judgement of multidisciplinary teams. Patients were followed from the date of radioembolisation to last contact or death and the nature and severity of all adverse events (AEs) recorded from medical records.RESULTS: Most radioembolisation candidates were Child-Pugh class A (82.5%) with multinodular HCC (75.9%) invading both lobes (53.1%); 56.3% were advanced stage. Radioembolisation was used first-line in 57.5% of patients and second-line in 34.2%. Common prior procedures were transarterial (chemo)embolisation therapies (27.1%), surgical resection/transplantation (17.2%) and ablation (8.6%). There was no difference in AE incidence and severity between prior treatment subgroups. Median (95% confidence interval [CI]) survival following radioembolisation was similar between procedure-naive and prior treatment groups for Barcelona Clinic Liver Cancer (BCLC) stage A: 22.1 months (15.1-45.9) versus 30.9 months (19.6-46.8); p = 0.243); stage B: 18.4 months (11.2-19.4) versus 22.8 months (10.9-34.2); p = 0.815; and stage C: 8.8 months (7.1-10.8) versus 10.8 months (7.7-12.6); p = 0.976.CONCLUSIONS: Radioembolisation is a valuable treatment option for patients who relapse following surgical, ablative or vascular procedures and remain suitable candidates for this treatment.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Carcinoma, Hepatocellular/radiotherapy
KW - Embolization, Therapeutic/adverse effects
KW - Female
KW - Humans
KW - Liver/radiation effects
KW - Liver Neoplasms/radiotherapy
KW - Male
KW - Middle Aged
KW - Retrospective Studies
KW - Safety
KW - Survival Analysis
KW - Young Adult
U2 - 10.1007/s00259-018-3968-5
DO - 10.1007/s00259-018-3968-5
M3 - Article
C2 - 29516130
VL - 45
SP - 1721
EP - 1730
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
SN - 1619-7070
IS - 10
ER -